vs
EXACT SCIENCES CORP（EXAS）与诺唯真游轮控股（LINE）财务数据对比。点击上方公司名可切换其他公司
诺唯真游轮控股的季度营收约是EXACT SCIENCES CORP的1.6倍（$1.4B vs $878.4M），诺唯真游轮控股净利率更高（-7.3% vs -9.8%，领先2.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs 3.1%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $35.0M）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
诺唯真游轮控股是一家总部位于美国、注册地为百慕大的企业，旗下全资运营诺唯真游轮、大洋游轮、丽晶七海游轮三大品牌，合并业务规模位列全球游轮运营商第三位，目前在纽约证券交易所挂牌上市。
EXAS vs LINE — 直观对比
营收规模更大
LINE
是对方的1.6倍
$878.4M
营收增速更快
EXAS
高出20.0%
3.1%
净利率更高
LINE
高出2.5%
-9.8%
自由现金流更多
EXAS
多$85.4M
$35.0M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.4B |
| 净利润 | $-86.0M | $-100.0M |
| 毛利率 | 70.1% | 32.3% |
| 营业利润率 | -9.4% | 2.5% |
| 净利率 | -9.8% | -7.3% |
| 营收同比 | 23.1% | 3.1% |
| 净利润同比 | 90.1% | 79.4% |
| 每股收益（稀释后） | $-0.45 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASLINE
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $1.4B | ||
| Q2 25 | $811.1M | $1.4B | ||
| Q1 25 | $706.8M | $1.3B | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.3B | ||
| Q2 24 | $699.3M | $1.3B | ||
| Q1 24 | $637.5M | $1.3B |
净利润EXASLINE
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $-100.0M | ||
| Q2 25 | $-1.2M | $-6.0M | ||
| Q1 25 | $-101.2M | $0 | ||
| Q4 24 | $-864.6M | $-71.0M | ||
| Q3 24 | $-38.2M | $-485.0M | ||
| Q2 24 | $-15.8M | $-68.0M | ||
| Q1 24 | $-110.2M | $-40.0M |
毛利率EXASLINE
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | 32.3% | ||
| Q2 25 | 69.3% | 31.9% | ||
| Q1 25 | 70.8% | 32.2% | ||
| Q4 24 | 69.0% | 32.3% | ||
| Q3 24 | 69.4% | 32.8% | ||
| Q2 24 | 69.8% | 33.4% | ||
| Q1 24 | 70.0% | 33.4% |
营业利润率EXASLINE
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | 2.5% | ||
| Q2 25 | -0.3% | 1.7% | ||
| Q1 25 | -13.6% | 4.3% | ||
| Q4 24 | -122.8% | -1.6% | ||
| Q3 24 | -5.6% | -38.6% | ||
| Q2 24 | -3.8% | 5.5% | ||
| Q1 24 | -16.7% | 7.6% |
净利率EXASLINE
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | -7.3% | ||
| Q2 25 | -0.1% | -0.4% | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | -5.3% | ||
| Q3 24 | -5.4% | -36.3% | ||
| Q2 24 | -2.3% | -5.1% | ||
| Q1 24 | -17.3% | -3.0% |
每股收益（稀释后）EXASLINE
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | $-0.44 | ||
| Q2 25 | $-0.01 | $-0.03 | ||
| Q1 25 | $-0.54 | $0.01 | ||
| Q4 24 | $-4.69 | $-0.52 | ||
| Q3 24 | $-0.21 | $-2.44 | ||
| Q2 24 | $-0.09 | $-0.46 | ||
| Q1 24 | $-0.60 | $-0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $8.4B |
| 总资产 | $5.9B | $19.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASLINE
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | $173.0M | ||
| Q3 24 | $1.0B | $409.0M | ||
| Q2 24 | $946.8M | $73.0M | ||
| Q1 24 | $652.1M | — |
股东权益EXASLINE
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $8.4B | ||
| Q2 25 | $2.5B | $8.6B | ||
| Q1 25 | $2.4B | $8.6B | ||
| Q4 24 | $2.4B | $8.6B | ||
| Q3 24 | $3.2B | $9.0B | ||
| Q2 24 | $3.2B | $4.9B | ||
| Q1 24 | $3.1B | $5.6B |
总资产EXASLINE
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $19.2B | ||
| Q2 25 | $5.8B | $19.4B | ||
| Q1 25 | $5.7B | $18.8B | ||
| Q4 24 | $5.9B | $18.7B | ||
| Q3 24 | $6.7B | $19.3B | ||
| Q2 24 | $6.7B | $18.8B | ||
| Q1 24 | $6.4B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $230.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $35.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 2.5% |
| 资本支出强度资本支出/营收 | 3.6% | 14.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASLINE
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $230.0M | ||
| Q2 25 | $89.0M | $258.0M | ||
| Q1 25 | $30.8M | $139.0M | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $186.0M | ||
| Q2 24 | $107.1M | $155.0M | ||
| Q1 24 | $-82.3M | $105.0M |
自由现金流EXASLINE
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | $35.0M | ||
| Q2 25 | $46.7M | $95.0M | ||
| Q1 25 | $-365.0K | $-12.0M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $33.0M | ||
| Q2 24 | $71.2M | $-31.0M | ||
| Q1 24 | $-120.0M | $-42.0M |
自由现金流率EXASLINE
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | 2.5% | ||
| Q2 25 | 5.8% | 7.0% | ||
| Q1 25 | -0.1% | -0.9% | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | 2.5% | ||
| Q2 24 | 10.2% | -2.3% | ||
| Q1 24 | -18.8% | -3.2% |
资本支出强度EXASLINE
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | 14.2% | ||
| Q2 25 | 5.2% | 12.1% | ||
| Q1 25 | 4.4% | 11.7% | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 11.5% | ||
| Q2 24 | 5.1% | 13.9% | ||
| Q1 24 | 5.9% | 11.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LINE
| Warehousing Operations | $883.0M | 64% |
| Other | $308.0M | 22% |
| Warehouse Lease | $60.0M | 4% |
| Food Sales | $52.0M | 4% |
| E Commerce And Other | $46.0M | 3% |
| Railcar Lease | $23.0M | 2% |
| Service Other | $5.0M | 0% |
